ArticleAmerican journal of preventive cardiology2026
Cost-effectiveness of a telephone health coaching and remote exercise monitoring for peripheral artery disease (TeGeCoach).
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The number of people with peripheral arterial disease (PAD) increased by almost 25% between 2000 and 2010. The economic burden on healthcare systems caused by PAD will continue to rise because of the aging population and a further increase in risk factors. The aim of the study was to examine the cost-effectiveness of the 12-month patient-centered 'Telephone Health Coaching and Remote Exercise Monitoring for Peripheral Artery Disease' (TeGeCoach) program in a randomized controlled trial. Methods This is a cost-effectiveness analysis based on a two-arm, parallel-group, open-label, pragmatic, randomized-controlled clinical trial conducted by three German statutory health insurance funds with follow-up assessments after 12 and 24 months. Claims data for the calculation of costs and questionnaire data for the quantification of quality-adjusted life years (QALYs) based on the EQ5D-5L were used. From a healthcare payer's perspective, cost-effectiveness was examined over 24 months follow-up using intention-to-treat (ITT) and modified ITT (mITT) and per protocol (PP) approaches. Results Assuming intervention costs of €672, the point estimates for the ITT analysis over 24 months showed non-significantly higher costs in the IG of €2003 and non-significantly higher QALYs of 0.02 compared to the control group. At a willingness to pay (WTP) threshold of €50,000, the probability of the TeGeCoach being cost-effective was 30%. Under the same assumptions, the mITT and the PP approach resulted in probabilities for cost-effectiveness of 79% and, 95%, respectively. Conclusion As demonstrated by the PP- and mITT-analysis, the treatment of PAD by TeGeCoach might be cost-effective under favorable assumptions. However, applying the stricter criteria represented by the ITT scenario, TeGeCoach couldn't demonstrate its cost-effectiveness. Therefore, before TeGeCoach should be used in healthcare practice, it is necessary to adapt the program implementation. The effectiveness of these adjustments should then be verified in further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.